vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

Impact · against what's priced in

The announcement is a net positive for vTv Therapeutics as it secures external funding for a new Phase 2 trial in type 2 diabetes, reducing capital burn and expanding the drug's total addressable market. While clinical trials are inherently risky, the shift of funding costs to M42 provides a concrete financial benefit.

VTVT+0.50

No priced-in read yet